These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25486195)

  • 1. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
    Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
    Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
    Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
    Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupting the scaffold, an alternative approach to inhibiting FAK.
    Chen S; Haas M; Sun S
    Cell Cycle; 2014; 13(24):3794-5. PubMed ID: 25457350
    [No Abstract]   [Full Text] [Related]  

  • 4. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
    Kurenova EV; Hunt DL; He D; Magis AT; Ostrov DA; Cance WG
    J Med Chem; 2009 Aug; 52(15):4716-24. PubMed ID: 19610651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
    Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
    Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
    Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
    Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
    Stewart JE; Ma X; Megison M; Nabers H; Cance WG; Kurenova EV; Beierle EA
    Mol Carcinog; 2015 Jan; 54(1):9-23. PubMed ID: 23868727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage.
    Taylor KN; Schlaepfer DD
    Mol Cancer Ther; 2018 Apr; 17(4):719-723. PubMed ID: 29610281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors.
    Moen I; Gebre M; Alonso-Camino V; Chen D; Epstein D; McDonald DM
    Clin Exp Metastasis; 2015 Dec; 32(8):799-817. PubMed ID: 26445848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
    Ucar DA; Kurenova E; Garrett TJ; Cance WG; Nyberg C; Cox A; Massoll N; Ostrov DA; Lawrence N; Sebti SM; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2012 Sep; 11(17):3250-9. PubMed ID: 22894899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
    Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
    Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
    Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
    Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of focal adhesion kinase inhibitors in cancer therapy.
    Ma WW
    Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic properties of caudatin in vitro and in vivo by suppression of VEGF‑VEGFR2‑AKT/FAK signal axis.
    Wang X; Fu X; Zhao S; Fu X; Zhang H; Shao L; Li G; Fan C
    Mol Med Rep; 2017 Dec; 16(6):8937-8943. PubMed ID: 28990104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.